

#8

Please type a plus sign (+) inside this box → (+)



PTO/SB08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031  
Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 2

## COMPLETE IF KNOWN

Application Number	10/069,630
Confirmation Number	3322
Filing Date	February 27, 2002
First Named Inventor	Robert Richard Dykstra
Group Art Unit	Not assigned
Examiner Name	Not assigned
Attorney Docket Number	7757

## U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	DOCUMENT NUMBER Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
AD	1	US-5,360,568	11/1/1994	Madison et al.	
AD	2	US-5,360,569	11/1/1994	Madison et al.	
AD	3	US-5,370,826	12/6/1994	Madison et al.	
AD	4	US-5,576,282	11/19/1996	Miracle et al.	
AD	5	US-5,817,614	10/6/1998	Miracle et al.	
AD	6	US-5,041,232	8/20/1991	Batal et al.	
AD	7	US-5,045,223	9/3/1991	Batal et al.	
AD	8	US-5,047,163	9/10/1991	Batal et al.	
AD	9	US-5,310,925	5/10/1994	Batal et al.	
AD	10	US-5,413,733	5/9/1995	Nicholson et al.	
AD	11	US-5,482,515	1/9/1996	Madison et al.	
AD	12	US-5,550,256	8/27/1996	Madison et al.	
AD	13	US-5,478,357	12/26/1995	Madison et al.	
AD	14	US-5,442,066	8/15/1995	Madison et al.	
AD	15	US-5,760,222	6/2/1998	Coope	
AD	16	US-5,753,599	5/19/1998	Coope et al.	
AD	17	US-5,652,207	7/29/1997	Ghatlia	
AD	18	US-4,505,908	3/19/1985	Zeugner et al.	
AD	19	US-4,325,957	4/20/1982	Zeugner et al.	
AD	20	US-4,096,141	6/20/1978	Milkowski et al.	
AD	21	US-4,595,531	6/17/1986	Milkowski et al.	
AD	22	US-4,194,987	3/25/1980	Brubaker	
AD	23	US-5,693,603	12/2/1997	Ghatlia	
AD	24	US-5,710,116	1/20/1998	Miracle et al.	
AD	25	US-6,007,583 (equivalent to EP 909 810)	12/28/1999	Nestler	
AD	26	US-6,120,557 (equivalent to EP 909 810)	9/19/2000	Nestler	
AD	27	US-5,952,282 (equivalent to EP 825 251)	9/14/1999	Löffler et al.	

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	FOREIGN PATENT DOCUMENT Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
AD	28	WO 98/23602	6/4/1998	The Clorox Co.		
AD	29	WO 95/13352	5/18/1995	Unilever		
AD	30	WO 95/13353	5/18/1995	Unilever		
AD	31	WO 95/13351	5/18/1995	Unilever		
AD	32	WO 97/06147	2/20/1997	Unilever		
AD	33	WO 98/23717	6/4/1998	Unilever		
AD	34	WO 98/15535	4/16/1998	Fujisawa Pharm.		
AD	35	WO 95/28399	10/26/1995	Glaxo Wellcome Inc.		
AD	36	WO 98/07825	2/26/1998	Unilever		
AD	37	CA 1,122,980 (equivalent to EP 004 024)	5/4/1982	Kalbe-Chemie Pharm.		

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

L. Nacht

5/1/04

7 of 2

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
17	38	H. Böhme et al., <i>Über Derivate des 1,2,3,4,5-Pentahydro-2-benzazepins</i> , Arch Pharm, Vol. 306 (4), 1972, pp. 271-274	
EXAMINER		DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of citation with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.